SGLT2 Inhibitors: A New Class of Diabetes Medication

When SGLT2 inhibitors first entered clinical practice, they were viewed primarily as another option for lowering blood glucose in Type 2 diabetes. Their mechanism was novel and somewhat counterintuitive: rather than helping the body process glucose more efficiently, they caused excess glucose to be excreted in the urine. The approach was effective, but its broader significance was not immediately apparent.

The picture changed quickly. Large clinical trials began showing benefits that extended well beyond blood glucose control. Patients taking SGLT2 inhibitors had fewer cardiovascular events, slower progression of kidney disease, and reduced hospitalization for heart failure. As the evidence accumulated, the medications were increasingly used not only for diabetes, but for heart failure and chronic kidney disease as well, including in patients who did not have diabetes at all.

What had appeared to be a glucose-lowering medication turned out to be a class of drugs with effects on multiple organ systems, addressing some of the most consequential complications of diabetes and several conditions that frequently accompany it. SGLT2 inhibitors are now one of the most important drug classes in modern internal medicine, with a clinical role that continues to expand.

For a complete overview of diabetes, see Diabetes: Causes, Symptoms, Diagnosis, Complications, and Modern Treatment (Complete Guide).

How SGLT2 Inhibitors Work

To understand SGLT2 inhibitors, it is helpful to start with how the kidneys handle glucose. Under normal circumstances, the kidneys filter large amounts of blood every day, and glucose is among the substances filtered out. Most of this glucose is then reabsorbed back into the bloodstream by specialized transporters in the kidney tubules, ensuring that glucose is conserved rather than lost in urine.

The most important of these transporters is called SGLT2, short for sodium-glucose cotransporter 2. SGLT2 is responsible for reabsorbing roughly 90 percent of the glucose that the kidneys filter. The remaining 10 percent is handled by a related transporter called SGLT1.

In healthy people, this system works efficiently. Glucose is filtered, reabsorbed, and returned to circulation. Almost no glucose appears in urine.

In people with diabetes, the system continues to function, but it is now reabsorbing glucose at concentrations much higher than the body needs. The kidneys, in effect, are conserving sugar that the body has too much of, contributing to the elevated blood glucose that defines diabetes.

SGLT2 inhibitors block the SGLT2 transporter, preventing the kidneys from reabsorbing as much glucose as they normally would. The unreabsorbed glucose is excreted in the urine, lowering blood glucose levels and producing several other effects in the process.

The mechanism is straightforward, but its consequences turn out to be far broader than glucose control alone.

The Medications in This Class

Several SGLT2 inhibitors are now in widespread use globally. They share the same basic mechanism but differ slightly in their effects, dosing, and approved indications.

Empagliflozin

Empagliflozin, marketed as Jardiance, has the most extensive clinical evidence base of the SGLT2 inhibitors. Major trials have shown its benefits in Type 2 diabetes, heart failure, and chronic kidney disease, and it is approved for use across all three indications.

Dapagliflozin

Dapagliflozin, marketed as Farxiga in some regions and Forxiga in others, has also demonstrated benefits across diabetes, heart failure, and kidney disease, with a similar approval profile.

Canagliflozin

Canagliflozin, marketed as Invokana, was one of the first SGLT2 inhibitors to demonstrate cardiovascular and kidney benefits in clinical trials, particularly in patients with diabetic kidney disease.

Ertugliflozin

Ertugliflozin, marketed as Steglatro, is also available, though it has a somewhat narrower clinical evidence base compared to the others.

The medications are taken orally, typically once daily, which makes them more convenient than injectable medications such as the GLP-1 receptor agonists.

For more on the GLP-1 class, see GLP-1 Medications: How Ozempic, Wegovy, and Mounjaro Work.

What These Medications Treat

Although SGLT2 inhibitors were originally developed for Type 2 diabetes, their indications have expanded considerably as evidence has accumulated.

Type 2 Diabetes

SGLT2 inhibitors produce modest but consistent reductions in hemoglobin A1c, typically lowering it by around 0.5 to 1 percent depending on baseline glucose control. They also produce modest weight loss, generally in the range of 2 to 4 kilograms, and modest reductions in blood pressure.

The glucose-lowering effects depend on kidney function. As kidney function declines, the medications become less effective at lowering glucose, though they retain other benefits.

Heart Failure

One of the most important developments in modern cardiology has been the recognition that SGLT2 inhibitors reduce hospitalizations and improve outcomes in heart failure. This benefit applies across heart failure subtypes, including patients with reduced ejection fraction and those with preserved ejection fraction.

Critically, the heart failure benefit is independent of diabetes. SGLT2 inhibitors are now used as standard therapy in heart failure even in patients without diabetes, representing a major shift in the role of this medication class.

For more on the cardiovascular dimensions of diabetes, see Diabetes and Heart Disease: The Cardiovascular Connection.

Chronic Kidney Disease

SGLT2 inhibitors slow the progression of chronic kidney disease, reduce the loss of kidney function over time, and decrease the risk of progression to end-stage kidney failure requiring dialysis or transplantation. Like the heart failure benefit, the kidney benefit applies in patients with and without diabetes.

This is a particularly significant development because kidney disease has historically had relatively few effective treatments, and the prospect of a medication that meaningfully slows progression has changed clinical management substantially.

For more on diabetic kidney disease specifically, see Diabetic Kidney Disease: How to Protect Your Kidneys.

Cardiovascular Disease in Diabetes

In patients with Type 2 diabetes and established cardiovascular disease or significant cardiovascular risk, SGLT2 inhibitors have been shown to reduce the risk of major cardiovascular events including heart attack, stroke, and cardiovascular death. The benefit appears most pronounced in patients with the highest baseline risk.

Why the Benefits Extend Beyond Glucose

The breadth of clinical benefits associated with SGLT2 inhibitors is not fully explained by their effects on blood glucose. Several mechanisms appear to contribute to the cardiovascular and kidney benefits observed in clinical trials.

Reduced Fluid Volume

By promoting glucose excretion in urine, SGLT2 inhibitors also promote sodium and water excretion. The result is a modest reduction in circulating fluid volume, which reduces the workload on the heart and kidneys. This effect contributes to lower blood pressure and reduced strain on the cardiovascular system.

Effects on Kidney Hemodynamics

SGLT2 inhibitors alter the way blood flows through the kidneys, reducing pressure within the small filtering units of the kidney called glomeruli. Elevated glomerular pressure is one of the central mechanisms through which diabetes and high blood pressure damage kidneys over time. Reducing this pressure appears to be one of the key reasons SGLT2 inhibitors slow the progression of kidney disease.

Metabolic Shifts

SGLT2 inhibitors produce subtle but meaningful shifts in metabolism, including increased use of ketones for energy by the heart and kidneys. Some researchers believe this metabolic shift contributes to the protective effects of these medications, though the full picture is still being characterized.

Anti-Inflammatory Effects

The medications appear to reduce certain markers of inflammation and oxidative stress, which may contribute to their broader cardiovascular and kidney benefits. The mechanisms are still being studied.

The combination of these effects, rather than any single one, likely accounts for the wide range of benefits observed across organ systems.

What to Expect from Treatment

For people considering or starting SGLT2 inhibitors, several practical considerations are worth understanding.

How They Are Taken

SGLT2 inhibitors are oral medications taken once daily, typically in the morning. Most do not require timing around meals, though specific dosing instructions vary by medication. The convenience of once-daily dosing is one of the practical advantages of this class.

Onset of Effects

The glucose-lowering effects of SGLT2 inhibitors begin within the first weeks of treatment, with full effects usually evident within two to three months. The cardiovascular and kidney benefits develop more gradually, with benefits accumulating over months to years of consistent use.

Common Side Effects

The most common side effect of SGLT2 inhibitors is genital fungal infection, particularly yeast infections, which result from the increased glucose in urine creating an environment favorable to fungal growth. These infections are usually mild and treatable, but they are common enough that patients should be aware of the possibility.

Urinary tract infections occur somewhat more frequently than in patients not taking these medications, though the magnitude of this increase is modest.

Volume depletion, including dizziness on standing or low blood pressure, can occur, particularly in patients also taking diuretics. Dose adjustments to other medications may be needed when SGLT2 inhibitors are started.

Less Common but More Serious Issues

A rare but serious complication is a condition called diabetic ketoacidosis, which can occur in patients taking SGLT2 inhibitors at lower blood glucose levels than typical for this condition, sometimes called euglycemic diabetic ketoacidosis. This is uncommon but important to recognize, particularly in patients undergoing surgery, fasting, or following very low-carbohydrate diets.

A small risk of lower limb amputation has been suggested in some studies, though this appears to be more strongly associated with specific medications and patient populations than with the class as a whole.

Patients with significant kidney disease at the time of starting SGLT2 inhibitors require careful monitoring, though, as noted earlier, these medications are often beneficial in kidney disease itself.

Who Benefits Most from These Medications

The clinical evidence has clarified which patients benefit most from SGLT2 inhibitors. Several groups have particularly clear indications.

Patients with Type 2 diabetes and established cardiovascular disease benefit from the cardiovascular protective effects, often making SGLT2 inhibitors a preferred option in this group regardless of baseline glucose control.

Patients with Type 2 diabetes and chronic kidney disease, particularly those with protein in the urine, benefit from the kidney-protective effects, with significant reductions in disease progression.

Patients with heart failure, with or without diabetes, benefit from the reduced hospitalization and improved outcomes.

Patients with chronic kidney disease, with or without diabetes, benefit from slowed disease progression.

Beyond these groups, SGLT2 inhibitors are also used as glucose-lowering medications in Type 2 diabetes more generally, though the choice of medication in any individual patient depends on the full clinical picture.

Comparing SGLT2 Inhibitors and GLP-1 Medications

Patients and physicians often face the question of how SGLT2 inhibitors compare to GLP-1 receptor agonists, the other major class of newer diabetes medications. The medications have different mechanisms, different effect profiles, and different ideal patient populations.

GLP-1 medications produce greater reductions in blood glucose and far greater weight loss than SGLT2 inhibitors. They also produce cardiovascular benefits, particularly in patients with established cardiovascular disease.

SGLT2 inhibitors produce more modest glucose and weight effects but provide stronger benefits in heart failure and kidney disease. They are also typically less expensive and more convenient, given that they are oral once-daily medications rather than injections.

In many clinical situations, the two classes are complementary rather than competing. Patients with multiple conditions, including diabetes, cardiovascular disease, and kidney disease, often benefit from both medications used together. The choice depends on the specific clinical priorities, patient preferences, and access to medications.

Considerations for Patients Without Diabetes

One of the more striking developments in recent years has been the use of SGLT2 inhibitors in patients without diabetes. The medications are now standard therapy in heart failure regardless of diabetes status, and they are increasingly used in chronic kidney disease in the same way.

This expansion has changed how the medications are categorized. They are no longer simply diabetes drugs that happen to have other benefits. They are cardio-renal-metabolic medications with applications across several conditions, of which diabetes is one.

For patients with heart failure or chronic kidney disease who do not have diabetes, the use of these medications often comes through cardiology or nephrology rather than endocrinology, and the framing of treatment is correspondingly different.

For more on when specialist evaluation is appropriate, see When Should You See an Endocrinologist for Diabetes?.

Practical Considerations for Long-Term Use

SGLT2 inhibitors are typically used as long-term therapy. The benefits they provide depend on continued use, and stopping the medications generally results in loss of the gains achieved during treatment.

Some practical considerations apply for patients on long-term therapy.

Hydration matters. The increased fluid loss associated with these medications means that adequate fluid intake is important, particularly during illness, travel, or hot weather.

Foot care, while always important in diabetes, deserves particular attention given the small possible association with foot complications. Regular foot examinations and prompt evaluation of any foot wounds remain important.

Periodic monitoring of kidney function, blood pressure, and electrolytes is part of standard care. Most patients tolerate the medications well over time, but monitoring allows early detection of any issues.

For surgical procedures, particularly major surgery, temporary discontinuation of SGLT2 inhibitors is usually recommended to reduce the risk of euglycemic diabetic ketoacidosis. Patients should always inform their surgical team about all medications they are taking.

The Broader Significance

The story of SGLT2 inhibitors illustrates something important about how medications can change medical practice. A class of drugs initially developed for one purpose, lowering blood glucose, turned out to have effects across multiple organ systems and now plays a central role in conditions that have nothing directly to do with diabetes.

This trajectory has reshaped how Type 2 diabetes is treated. Glucose lowering, while still important, is no longer the only consideration. Modern guidelines emphasize cardiovascular risk reduction, kidney protection, and quality of life as central goals, with medications selected accordingly.

The broader implication is that diabetes is increasingly understood as a disease to be managed in the context of the whole body, with medications chosen for their effects across multiple systems rather than for any single endpoint. SGLT2 inhibitors have been instrumental in this shift, demonstrating that effective treatment can address several major complications simultaneously.

Conclusion

SGLT2 inhibitors are among the most important medication classes to enter clinical practice in recent decades. Their mechanism is novel, their effects extend across multiple organ systems, and their benefits in cardiovascular disease and kidney disease have expanded their use far beyond the original indication of Type 2 diabetes.

For patients with diabetes, particularly those with cardiovascular disease or kidney involvement, these medications often play a central role in modern treatment. For patients with heart failure or chronic kidney disease, with or without diabetes, they have become standard therapy that meaningfully changes long-term outcomes.

Side effects are real and deserve attention, but for most patients they are manageable. The evidence base supporting these medications is among the strongest in modern internal medicine, and ongoing research continues to refine understanding of their effects and indications.

For people navigating diabetes, heart disease, or kidney disease, SGLT2 inhibitors represent one of the most significant additions to the treatment landscape in many years. The decision to use them is best made in consultation with a physician familiar with the full clinical context, but their availability has changed what is possible in addressing some of the most consequential chronic diseases of modern life.

Medical Disclaimer

This content is for informational purposes only and does not constitute medical advice. Individuals should consult a qualified healthcare provider for diagnosis and treatment.